Fortrea reports Q3 2026 results, raises full‑year guidance but EPS misses consensus

Fortrea Holdings posted third‑quarter 2026 revenue of $691.5 million and adjusted earnings per share of $0.28, missing the consensus estimate of $0.63. The company raised its full‑year revenue outlook to $2.665‑$2.690 billion and adjusted EBITDA to $210‑$218 million, while noting a $45 million cash acquisition of Worldwide Clinical Trials’ Early Phase Services. Despite the guidance lift, the stock fell about 11% in pre‑market trading.

The EPS miss triggered an 11% pre‑market price decline, reflecting investor disappointment. The higher full‑year guidance may support future upside if the early‑phase acquisition drives margin expansion.

  • 1Q3 2026 revenue was $691.5 million.
  • 2Adjusted EPS for the quarter was $0.28.
  • 3Adjusted EBITDA for the quarter was $58.0 million.
  • 4Full‑year 2026 revenue guidance was raised to $2.665 billion‑$2.690 billion.
  • 5Full‑year 2026 adjusted EBITDA guidance was raised to $210 million‑$218 million.
  • 6Fortrea acquired Worldwide Clinical Trials’ Early Phase Services for approximately $45 million in cash.

Sources